Our website use cookies to improve and personalize your experience and to display advertisements (if any). Our website may also include cookies from third parties like Google Adsense, Google Analytics, and Youtube. By using the website, you consent to the use of cookies.

Ok, I Agree
Aug
06
2021
By The African Mirror
Moderna says its shot remains 93% effective

Moderna says its shot remains 93% effective

COVID-19
MICHAEL ERMAN MODERNA Inc has revealed that its COVID-19 shot was about 93% effective four to six months after the second dose, showing hardly any change from the 94% efficacy reported in its original clinical trial. That compares favourably to data released by rivals Pfizer Inc and BioNTech SE last week in which they suggested their vaccine's efficacy waned around 6% every two months, declining to around 84% six months after the second shot. Both the Moderna and Pfizer-BioNTech vaccines are based on messenger RNA (mRNA) technology. "We are very pleased that our COVID-19 vaccine efficacy is stable at 93%…
Read More
Jul
27
2021
By The African Mirror
Mixed AstraZeneca-Pfizer shot boosts COVID antibody level – study

Mixed AstraZeneca-Pfizer shot boosts COVID antibody level – study

COVID-19
SANGMI CHA A mixed vaccination of first AstraZeneca and then a Pfizer COVID-19 shot boosted neutralizing antibody levels by six times compared with two AstraZeneca doses, a study from South Korea showed. The study involved 499 medical workers - 100 receiving mixed doses, 200 taking two doses of the Pfizer/BioNTech shot and the remainder getting two AstraZeneca shots. All showed neutralizing antibodies, which prevent the virus from entering cells and replicating, and the result of the mixed schedule of vaccines showed similar amounts of neutralizing antibodies found from the group that received two Pfizer shots. A British study last month…
Read More
Jan
19
2021
By The African Mirror
WHO close to vaccine deal for the poor

WHO close to vaccine deal for the poor

COVID-19
EMMA FARGE and STEPHANIE NEBEHAY THE World Health Organization is in advanced negotiations with Pfizer to include the firm's COVID-19 shot in the body's vaccine-sharing scheme, which would speed vaccine deliveries to poorer countries, according to a senior WHO official. The COVAX scheme -- led by the WHO and GAVI vaccine alliance -- is due to start rolling out vaccines to poor and middle-income countries in February, with 2 of 3 billion doses expected to be delivered this year. "We are in ... detailed discussions with Pfizer. We believe very soon we will have access to that product," WHO senior…
Read More
Facebook
Twitter
Linkedin
Instagram